These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37072306)

  • 21. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
    Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
    JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent radiotherapy cannot provide superiority of surgical oncological outcome and long-term survival rate in locally advanced esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy followed by minimally invasive esophagectomy.
    Wang YJ; Bao T; Li KK; Xie XF; He XD; Zhao XL; Guo W
    Surg Endosc; 2023 Sep; 37(9):7073-7082. PubMed ID: 37380741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials.
    Yang Y; Shao R; Cao X; Chen M; Gong W; Ying H; Song G; You G; Qiu G; Chen Q; Ji Y; Xu D
    Radiother Oncol; 2024 Nov; 200():110517. PubMed ID: 39218039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
    Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
    Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
    Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
    Front Immunol; 2022; 13():970534. PubMed ID: 36275724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma.
    Leng XF; Daiko H; Han YT; Mao YS
    Ann N Y Acad Sci; 2020 Dec; 1482(1):213-224. PubMed ID: 33067818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random.
    Qian D; Chen X; Shang X; Wang Y; Tang P; Han D; Jiang H; Chen C; Zhao G; Zhou D; Cao F; Er P; Zhang W; Li X; Zhang T; Zhang B; Guan Y; Wang J; Yuan Z; Yu Z; Wang P; Pang Q
    Radiother Oncol; 2022 Sep; 174():1-7. PubMed ID: 35764191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
    Murakami Y; Hamai Y; Emi M; Hihara J; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Kimura T; Okada M; Nagata Y
    J Radiat Res; 2018 Sep; 59(5):616-624. PubMed ID: 29939306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis.
    Wang Z; Shao C; Wang Y; Duan H; Pan M; Zhao J; Wang J; Ma Z; Li X; Yan X
    Int J Surg; 2022 Aug; 104():106767. PubMed ID: 35840049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
    Xu J; Cai Y; Hong Z; Duan H; Ke S
    Int J Surg; 2024 Jan; 110(1):490-506. PubMed ID: 37800587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. To radiate or not to radiate: that is the question?-a commentary on "Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial".
    Chandra R; Reznik SI
    Chin Clin Oncol; 2023 Dec; 12(6):60. PubMed ID: 37731309
    [No Abstract]   [Full Text] [Related]  

  • 33. [Research progress and challenges of neoadjuvant therapy for esophageal squamous cell carcinoma].
    Zhang HD; Liang HG; Tang P; Yu ZT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):836-842. PubMed ID: 34530568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neoadjuvant chemoradiotherapy or chemotherapy for locally advanced esophageal cancer?].
    Babic B; Fuchs HF; Bruns CJ
    Chirurg; 2020 May; 91(5):379-383. PubMed ID: 32140748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
    Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
    BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis.
    Wang H; Li S; Liu T; Chen J; Dang J
    Front Immunol; 2022; 13():998620. PubMed ID: 36177019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
    He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
    Front Immunol; 2022; 13():853922. PubMed ID: 35720312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
    Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Lordick F; D'Journo XB; Cerfolio RJ; Korst RJ; Novoa NM; Swanson SJ; Brunelli A; Ismail M; Fernando HC; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J;
    J Clin Oncol; 2018 Sep; 36(27):2796-2803. PubMed ID: 30089078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival Comparison Among Neoadjuvant Chemoradiotherapy Followed by Esophagectomy, Definitive Chemoradiotherapy, and Esophagectomy Alone for Esophageal Squamous Cell Carcinoma.
    Chen HS; Lin CH; Wu SC; Wang BY
    Ann Surg Oncol; 2022 Jun; 29(6):3617-3627. PubMed ID: 34994899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.